Exelixis (NASDAQ: EXEL) and Cascadian Therapeutics (NASDAQ:CASC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Exelixis and Cascadian Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exelixis 0 5 6 0 2.55
Cascadian Therapeutics 1 1 3 0 2.40

Exelixis presently has a consensus price target of $25.08, indicating a potential downside of 3.42%. Cascadian Therapeutics has a consensus price target of $6.00, indicating a potential upside of 67.13%. Given Cascadian Therapeutics’ higher probable upside, analysts plainly believe Cascadian Therapeutics is more favorable than Exelixis.


This table compares Exelixis and Cascadian Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Exelixis 18.20% 80.43% 13.93%
Cascadian Therapeutics N/A -42.30% -39.68%

Valuation and Earnings

This table compares Exelixis and Cascadian Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Exelixis $319.67 million 23.88 $95.32 million $0.19 136.69
Cascadian Therapeutics N/A N/A -$47.29 million ($1.61) -2.23

Exelixis has higher revenue and earnings than Cascadian Therapeutics. Cascadian Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

79.2% of Exelixis shares are owned by institutional investors. Comparatively, 82.6% of Cascadian Therapeutics shares are owned by institutional investors. 5.1% of Exelixis shares are owned by insiders. Comparatively, 20.7% of Cascadian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Exelixis has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Cascadian Therapeutics has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500.


Exelixis beats Cascadian Therapeutics on 8 of the 12 factors compared between the two stocks.

Exelixis Company Profile

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company’s CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company’s XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.